Skip to main content
. Author manuscript; available in PMC: 2014 Feb 25.
Published in final edited form as: Expert Opin Investig Drugs. 2012 Sep 26;21(12):1851–1859. doi: 10.1517/13543784.2012.733695

Table 2.

Comparison of key chemical and structural properties of tivozanib and sorafenib.27, 48 Sorafenib served as a comparator to tivozanib in the phase III TIVO-1 study in mRCC.

Characteristic Tivozanib Sorafenib
MW 454.863 464.824
VEFR1 IC50 0.21 nmol/L 26 nmol/L
VEFR2 IC50 0.16 nmol/L 90 nmol/L
VEFR3 IC50 0.24 nmol/L 100 nmol/L
2-D Structure graphic file with name nihms517990t1.jpg graphic file with name nihms517990t2.jpg
3-D Structure graphic file with name nihms517990t3.jpg graphic file with name nihms517990t4.jpg